Evidence map›Paper›PMID 29317618›Full record

ArticleNature communications2018

Development of an oral once-weekly drug delivery system for HIV antiretroviral therapy.

Ameya R Kirtane, Omar Abouzid, Daniel Minahan, Taylor Bensel, Alison L Hill, Christian Selinger, Anna Bershteyn, Morgan Craig, Shirley S Mo, Hormoz Mazdiyasni and 15 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers.

0numbers the graph read from it
0cells of the map it votes in
69citing papers in PubMed
15.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

69 citing papers in PubMed, 225 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Towards multifunctional robotic pills.Nature biomedical engineering · 2024
    Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

9 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 6 institutions in 2 countries.

Ameya R KirtaneDepartment of Chemical Engineering and David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.ORCID http://orcid.org/0000-0002-3779-0363
Omar AbouzidDepartment of Chemical Engineering and David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.
Daniel MinahanDepartment of Chemical Engineering and David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.
Taylor BenselDepartment of Chemical Engineering and David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.
Alison L HillProgram for Evolutionary Dynamics, Harvard University, Cambridge, Massachusetts, 02138, USA.ORCID http://orcid.org/0000-0002-6583-3623
Christian SelingerInstitute for Disease Modeling, Bellevue, WA, 98005, USA.
Anna BershteynInstitute for Disease Modeling, Bellevue, WA, 98005, USA.
Morgan CraigProgram for Evolutionary Dynamics, Harvard University, Cambridge, Massachusetts, 02138, USA.
Shirley S MoProgram for Evolutionary Dynamics, Harvard University, Cambridge, Massachusetts, 02138, USA.
Hormoz MazdiyasniDepartment of Chemical Engineering and David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.
Cody ClevelandDepartment of Chemical Engineering and David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.ORCID http://orcid.org/0000-0002-2973-8530
Jaimie RognerDepartment of Chemical Engineering and David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.
Young-Ah Lucy LeeDepartment of Chemical Engineering and David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.
Lucas BoothDepartment of Chemical Engineering and David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.
Farhad Javid
Sarah J WuDepartment of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.
Tyler GrantLyndra Inc, Watertown, MA, 02472, USA.
Andrew M BellingerLyndra Inc, Watertown, MA, 02472, USA.
Boris NikolicBiomatics Capital, 1107 1st Avenue, Apartment 1305, Seattle, WA, 98101, USA.
Alison HaywardDepartment of Chemical Engineering and David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.
Lowell WoodInstitute for Disease Modeling, Bellevue, WA, 98005, USA.
Philip A EckhoffInstitute for Disease Modeling, Bellevue, WA, 98005, USA.ORCID http://orcid.org/0000-0002-1278-3765
Martin A NowakProgram for Evolutionary Dynamics, Harvard University, Cambridge, Massachusetts, 02138, USA.ORCID http://orcid.org/0000-0001-5489-0908
Robert LangerDepartment of Chemical Engineering and David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA. rlanger@mit.edu.
Giovanni TraversoDepartment of Chemical Engineering and David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA. ctraverso@bwh.harvard.edu.ORCID http://orcid.org/0000-0001-7851-4077
Massachusetts Institute of Technology · USBellevue Hospital Center · USHarvard University · USBrigham and Women's Hospital · USLyndra Therapeutics (United States) · USInstitut National des Sciences Appliquées de Lyon · FR

Funding

The impact of HIV viral diversity and cellular immunity on HIV pathogenesisP30AI060354 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI ROBERT A. PARKER · 2004 to 2026
$94.4M
Development of Ultra Long-Acting Oral HIV TherapiesR01AI131416 · NIAID · LYNDRA THERAPEUTICS, INC. · PI ZALE, STEPHEN · 2017 to 2021
$6.5M
CONTROLLED RELEASE OF MACROMOLECULESR01EB000244 · NIBIB · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI LANGER, ROBERT SAMUEL, TRAVERSO, CARLO GIOVANNI · 2002 to 2021
$6.1M
Controlled Release of MacromoleculesR37EB000244 · NIBIB · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI LANGER, ROBERT SAMUEL · 2008 to 2017
$3.9M
Quantification and prediction of treatment efficacy for HIV cure strategiesDP5OD019851 · OD · JOHNS HOPKINS UNIVERSITY · PI HILL, ALISON LYNN · 2014 to 2018
$2.1M
NIAID NIH HHS P30 AI060354NIAID NIH HHS R01 AI131416NIBIB NIH HHS R01 EB000244NIBIB NIH HHS R37 EB000244NIH HHS DP5 OD019851
6 · The paper itself

Abstract

The efficacy of antiretroviral therapy is significantly compromised by medication non-adherence. Long-acting enteral systems that can ease the burden of daily adherence have not yet been developed. Here we describe an oral dosage form composed of distinct drug-polymer matrices which achieved week-long systemic drug levels of the antiretrovirals dolutegravir, rilpivirine and cabotegravir in a pig. Simulations of viral dynamics and patient adherence patterns indicate that such systems would significantly reduce therapeutic failures and epidemiological modelling suggests that using such an intervention prophylactically could avert hundreds of thousands of new HIV cases. In sum, weekly administration of long-acting antiretrovirals via a novel oral dosage form is a promising intervention to help control the HIV epidemic worldwide.

Indexed as

Administration, OralAnimalsAnti-HIV AgentsDiketopiperazinesDolutegravirDrug Delivery SystemsDrug Evaluation, PreclinicalHeterocyclic Compounds, 3-RingHumansModels, TheoreticalOxazinesPatient CompliancePiperazinesProof of Concept StudyPyridonesRilpivirineAnti-HIV AgentscabotegravirDiketopiperazinesDolutegravirHeterocyclic Compounds, 3-RingOxazinesPiperazinesPyridonesRilpivirine

Identifiers

PMID29317618
PMCPMC5760734
OpenAlexW2781350987

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.